戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 s achieved without dose-limiting toxicity or maximally tolerated dose.
2 was standardized to enalapril 40 mg/d or the maximally tolerated dose.
3 d dose-limiting, with 36 microg/kg being the maximally tolerated dose.
4  three- to fivefold above their conventional maximally tolerated dose.
5 t and during adenosine and dobutamine at the maximally tolerated dose.
6 ion was stopped and 75 micrograms/kg was the maximally tolerated dose.
7 level of 50 mg/m(2) was determined to be the maximally tolerated dose.
8 orticoid receptor) antagonist, at maximal or maximally tolerated doses.
9 nude mice when both drugs were used at their maximally tolerated doses.
10 angiotensin receptor blocker), at maximal or maximally tolerated doses.
11 eficient mice in a dose-dependent pattern at maximally tolerated doses.
12 ules of administration argues for the use of maximally tolerated doses.
13 , with all agents administered at maximum or maximally tolerated doses.
14 ting beta-blockers that may aid in achieving maximally tolerated doses.
15 trials should effective biological dose, not maximally tolerated dose, be used to determine phase II
16 , frequent drug administration at lower than maximally tolerated doses can improve activity while red
17 tely 10% mortality and was identified as the maximally tolerated dose in this model.
18  dose level, which defined 800 microg as the maximally tolerated dose in this trial.
19     Treatment according to an individualized maximally tolerated dose may achieve a comparable respon
20                                          The maximally tolerated dose (MTD) approach in conventional
21 , controlled, blinded trial to determine the maximally tolerated dose (MTD) of 3K3A-APC in ischemic s
22 phase I trial was conducted to determine the maximally tolerated dose (MTD) of concurrent weekly doce
23          Systemic toxicities established the maximally tolerated dose (MTD) of IL-2 as 15 MIU/day.
24   The primary objective was to determine the maximally tolerated dose (MTD).
25                   In this Phase I study, the maximally tolerated doses (MTDs) of i.p. iododeoxyuridin
26 ere enrolled (0.04, 0.15, 0.4 mg), because a maximally tolerated dose of 1.0 mg was identified in a p
27 00 mg/kg per day was comparable to that of a maximally tolerated dose of cyclophosphamide.
28  after at least 10 weeks of treatment with a maximally tolerated dose of paroxetine.
29 rolled BP, despite adherence to therapy with maximally tolerated doses of a beta -blocker, a long-act
30  a stable antihypertensive regimen including maximally tolerated doses of at least 3 drugs including
31  a stable antihypertensive regimen involving maximally tolerated doses of at least three drugs, inclu
32 atients who had active AAV despite receiving maximally tolerated doses of cyclophosphamide or had con
33 gurgitation who remained symptomatic despite maximally tolerated doses of GDMT were randomized 1:1 to
34 obin level (7.0 to 10.0%) who were receiving maximally tolerated doses of metformin and sulfonylurea
35 h inadequately controlled type 2 diabetes on maximally tolerated doses of metformin, sulphonylurea, o
36 despite treatment for at least 3 months with maximally tolerated doses of three drugs, from 12 second
37  treatment-resistant hypertension on stable, maximally tolerated doses of three or more drugs includi
38 ated up to 10 x 10(7) cells per dose, as the maximally tolerated dose regimen.
39 axol could be administered together at their maximally tolerated doses to tumor-bearing mice.
40 any oncology drugs are administered at their maximally tolerated dose without the knowledge of their